Regulatory Reform Outcomes and Accelerated Regulatory Pathways for New Prescription Medicines in Australia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2168-4804
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Regulatory Reform Outcomes and Accelerated Regulatory Pathways for New Prescription Medicines in Australia ; day:21 ; month:10 ; year:2022 ; pages:1-16
Therapeutic innovation & regulatory science ; (21.10.2022), 1-16
- Urheber
-
Yoffe, Alina
Liu, Johnson
Smith, Greg
Chisholm, Orin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s43441-022-00465-2
- URN
-
urn:nbn:de:101:1-2023010709045555667986
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yoffe, Alina
- Liu, Johnson
- Smith, Greg
- Chisholm, Orin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Is Medicines Parallel Trade "Regulatory Arbitrage'"?
Is medicines parallel trade ‘regulatory arbitrage’?
Regulatory roadmap for nanotechnology based medicines
Regulatory requirements and labeling of commercially available prescription (oral) medicines in Sri Lanka: there is room for improvement
Requirements for generic anti-epileptic medicines: a regulatory perspective
Ocular medicines in children: the regulatory situation related to clinical research
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
Geographies of regulatory disparity underlying Australia’s energy transition
Regulatory agencies and regulatory risk
Regulatory agencies and regulatory risk
Upgrading the ICT Regulatory Framework: Toward Accelerated and Inclusive Digital Connectivity
International Regulatory Collaboration on the Analysis of Nitrosamines in Metformin-Containing Medicines
Is Medicines Parallel Trade "Regulatory Arbitrage'"?
Is medicines parallel trade ‘regulatory arbitrage’?
Regulatory roadmap for nanotechnology based medicines
Regulatory requirements and labeling of commercially available prescription (oral) medicines in Sri Lanka: there is room for improvement
Requirements for generic anti-epileptic medicines: a regulatory perspective
Ocular medicines in children: the regulatory situation related to clinical research
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
Geographies of regulatory disparity underlying Australia’s energy transition
Regulatory agencies and regulatory risk
Regulatory agencies and regulatory risk
Upgrading the ICT Regulatory Framework: Toward Accelerated and Inclusive Digital Connectivity
International Regulatory Collaboration on the Analysis of Nitrosamines in Metformin-Containing Medicines
Is Medicines Parallel Trade "Regulatory Arbitrage'"?
Is medicines parallel trade ‘regulatory arbitrage’?
Regulatory roadmap for nanotechnology based medicines
Regulatory requirements and labeling of commercially available prescription (oral) medicines in Sri Lanka: there is room for improvement
Requirements for generic anti-epileptic medicines: a regulatory perspective
Ocular medicines in children: the regulatory situation related to clinical research
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
Geographies of regulatory disparity underlying Australia’s energy transition
Regulatory agencies and regulatory risk
Regulatory agencies and regulatory risk
Upgrading the ICT Regulatory Framework: Toward Accelerated and Inclusive Digital Connectivity